

1 **R Functions for Analysis of Continuous Glucose Monitor Data**

2 Tim Vigers^{1,2,3*}, B.A., Christine L. Chan¹, M.D., Janet Snell-Bergeon², Ph.D., Petter Bjornstad¹,
3 M.D., Philip S. Zeitler¹, M.D., Ph.D., Gregory Forlenza², M.D., Laura Pyle^{1,2,3}, Ph.D.

4
5 ¹Department of Pediatric Endocrinology, University of Colorado School of Medicine, Aurora,
6 Colorado, United States

7
8 ²Barbara Davis Center, University of Colorado School of Medicine, Aurora, Colorado, United
9 States

10
11 ³Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora,
12 Colorado

13
14
15 *Corresponding Author
16 Laura.pyle@ucdenver.edu (LP)

17

18 **Abstract:**

19 Continuous glucose monitoring (CGM) is an essential part of diabetes care. Real-time
20 CGM data are beneficial to patients for daily glucose management, and aggregate summary
21 statistics of CGM measures are valuable to direct insulin dosing and as a tool for researchers in
22 clinical trials. Yet, the various commercial systems still report CGM data in disparate, non-
23 standard ways. Accordingly, there is a need for a standardized, free, open-source approach to
24 CGM data management and analysis. Functions were developed in the free programming
25 language R to provide a rapid, easy, and consistent methodology for CGM data management and
26 analysis. Summary variables calculated by our package compare well to those generated by
27 various CGM software, and our functions provide a more comprehensive list of summary
28 measures available to clinicians and researchers. Consistent handling of CGM data using our R
29 package may facilitate collaboration between research groups and contribute to a better
30 understanding of free-living glucose patterns.

31

32 **Introduction**

33 Continuous glucose monitoring (CGM) technology has transformed diabetes care over
34 the past 15 years by allowing clinicians to measure free-living glucose patterns. During this
35 period, CGM use has increased from < 5% of patients to almost 50% in some age groups [1].
36 With recent reports detailing the benefits of CGM time in range metrics as predictive of long-
37 term vascular outcomes [2] and as an indicator of glucose management or estimated hemoglobin
38 A1c (HbA1c) [3], CGM use will likely continue to increase in both research and clinical settings.
39 Despite the increasing use of CGM for treatment and research, a standardized, free, open-source
40 approach to data management and analysis is lacking [4].

41 CGM manufacturers use proprietary algorithms to create reports and calculate summary
42 measures for patients and clinicians. As a result, it may be difficult to compare results obtained
43 using different CGM devices and to understand the sources of variability that could influence
44 CGM outcomes. In addition, research questions may require summary measures that are not
45 available in accompanying reports (e.g., use of a different cut-point for hyperglycemia).
46 Furthermore, use of the summary values provided by each CGM platform sometimes requires
47 that data be entered by hand into a database or spreadsheet prior to analysis. This is a time-
48 consuming and error prone process that will benefit from automation. The use of a free and open
49 source program to analyze raw sensor glucose values will enable researchers to define their own
50 variables of interest and standardize calculation of summary measures across different CGM
51 devices.

52 There have already been a few attempts to develop such systems, including the EasyGV
53 macro-enabled Excel workbook [5], AGP Report (agpreport.org), and Tidepool (tidepool.org).
54 However, there are reports suggesting that EasyGV poorly matches other calculations of mean

55 amplitude of glycemic excursion (MAGE) [6], and it does not permit the various definitions of a
56 significant excursion (i.e. greater than 1 standard deviation (SD), 2 SDs, etc.). Although
57 Tidepool appears to be an excellent option for patients and clinicians, it is not free for use in
58 research, and many smaller investigator-initiated studies cannot afford the additional expense.
59 Also, their open source code requires significant coding knowledge in multiple programming
60 languages which limits accessibility and widespread use.

61 To address this need, we have developed a package written entirely in the statistical
62 programming language R (R Foundation for Statistical Computing, Vienna, Austria). The
63 package currently works with data from Diasend (www.diasend.com), Dexcom
64 (www.dexcom.com), iPro 2 (<http://professional.medtronicdiabetes.com/ipro2-professional-cgm>),
65 Libre (www.freestylelibre.us), and Carelink ([www.medtronicdiabetes.com/products/carelink-](http://www.medtronicdiabetes.com/products/carelink-personal-diabetes-software)
66 [personal-diabetes-software](http://www.medtronicdiabetes.com/products/carelink-personal-diabetes-software)), with plans to add support for other platforms as CGM technology
67 advances. Additionally, data can be manually formatted to work with these functions if
68 necessary. The package is available on The Comprehensive R Archive Network (CRAN) under
69 the name ‘cgmanalysis’ and the source code can be found at
70 <https://github.com/childhealthbiostatistics/R-Packages>, which allows for version control and
71 forking if users need to alter functionality, and includes a short user guide for those with limited
72 R experience.

73

74 **Summary Measures of Glycemia**

75 Although CGM is not a new technology, there is still debate regarding the advantages
76 and disadvantages of various CGM metrics for use in clinical care and as research outcomes. The
77 American Diabetes Association (ADA) recently proposed a set of key metrics for CGM analysis

78 [7], all of which are calculated by our code, in addition to the glucose management index (GMI)
79 [3], time in range [2], and other variables proposed by Hernandez et al.[8]. An easy method to
80 calculate these important summary variables from a variety of sources of CGM data has the
81 potential to contribute to the standardization of the use of these metrics. A list of summary
82 variables produced by our default code is available in **Table 1**, and **Table 2** provides
83 comparisons between the package and proprietary software. The code can be easily modified to
84 include further variables of interest, to be released in future version updates. Further, because the
85 package is open source, individual users can create their own modifications.

86

87 **Methods**

88 **Package Design**

89 Our package consists of three simple functions: `cleandata()`, `cgmvariables()`, and
90 `cgmreport()`. The data cleaning function iterates through a directory of CGM data exports and
91 produces new files that then serve as input to the CGM variable calculator and the CGM report
92 generator. The initial directory can contain files from different sources, as the function identifies
93 the relevant timestamp and glucose values for each file format. By default, the cleaning function
94 will fill in gaps in glucose data less than 20 minutes long using linear interpolation. It will also
95 remove 24-hour periods containing gaps larger than 20 minutes, so that there will be an equal
96 number of daytime and nighttime values, important for calculating some variables, such as AUC.
97 The user can specify a different maximum gap to fill by interpolation and can also choose
98 whether to remove days with larger gaps. Ideally, the CGM data should be exported and then
99 cleaned using this package, and not manually edited. However, if a file does require manual data

100 editing, these functions will work on the three-column format detailed in the package
 101 documentation.

102 Once the data have been cleaned, the CGM variables described in **Table 1** are calculated
 103 using the `cgmvariables()` function. By default, blood glucose must be above a threshold for at
 104 least 35 minutes or below a threshold for at least 10 minutes to count as an excursion, but these
 105 parameters can be changed by the user if necessary. Likewise, daytime (e.g. for daytime vs.
 106 nighttime AUC or maximum glucose) is defined as 6:00 to 22:00 by default, but these can be set
 107 depending on user needs. MAGE is calculated using Baghurst’s algorithm [9], which we have
 108 coded in R. By default, the function includes blood glucose excursions greater than 1 SD from
 109 the mean in calculation of MAGE, but there are options for 1.5 SD and 2 SD as well.

110 **Table 1: Summary Measures of Glycemia**

CGM Variable	Definition
<code>percent_cgm_wear</code>	The number of sensor readings as a percentage of the number of potential readings (given time worn).
<code>average_sensor</code>	Mean of all sensor glucose values
<code>estimated_a1c</code>	Estimated HbA1c based on the equation: $(46.7 + \text{average glucose in mg/dL}) / 28.7[1]$
<code>gmi</code>	Glucose management indicator based on the equation: $3.31 + (0.02392 \times \text{average glucose in mg/dL})^7$
<code>q1_sensor</code>	First quartile sensor glucose value
<code>median_sensor</code>	Median sensor glucose value
<code>q3_sensor</code>	Third quartile sensor glucose value
<code>standard_deviation</code>	Standard deviation of all sensor glucose values
<code>cv</code>	Coefficient of variation of all sensor glucose values (SD/mean)
<code>min_sensor</code>	Minimum of all sensor glucose values
<code>max_sensor</code>	Maximum of all sensor glucose values
<code>excursions_over_***</code>	The number of local glucose peaks with an amplitude greater than *** mg/dL
<code>min_spent_over_***</code>	The total length of time that sensor glucose was at or above *** mg/dL
<code>percent_time_over_***</code>	Minutes spent above *** mg/dL, as a

	percentage of the total time CGM was worn
avg_excur_over_***_per_day	The number of glucose peaks above *** mg/dL averaged per 24-hour period of CGM wear
min_spent_under_**	The total length of time that sensor glucose was at or below ** mg/dL
percent_time_under_**	Minutes spent below ** mg/dL, as a percentage of the total time CGM was worn
min_spent_70_180	Minutes spent in the range 70 – 180 mg/dL (inclusive)
percent_time_70_180	Minutes spent in the range 70 – 180 mg/dL (inclusive), as a percentage of the total time CGM was worn
daytime_***	*** of all sensor glucose values during specified daytime hours
nighttime_***	*** of all sensor glucose values during specified nighttime hours
auc	Approximate area under the sensor glucose curve, calculated using the trapezoidal rule
r_mage	MAGE calculated according to Baghurst's algorithm
j_index	Calculated based on the equation: $0.324 \times (\text{average glucose in mg/dL} + \text{standard deviation of glucose levels})^2$ ¹¹
conga	Continuous overall net glycemic action, default n = 1 hour ¹¹
modd	Mean of daily differences
lbgi	Low blood glucose index
hbgi	High blood glucose index

111
 112 Our code was originally written to produce data tables for upload to a Research
 113 Electronic Data Capture (REDCap) database [10], which influenced the selection of variable
 114 names in the final output. These names can be changed in the code itself or by simply editing the
 115 function's output. These variables are stored in separate columns of a new data frame (the
 116 function's output), with each record identified by the patient ID.

117 In addition to producing calculated variables, our package can also plot CGM data in a
 118 few ways. First, the function concatenates all the CGM data in the specified directory into one
 119 data table and plots the aggregate data in the style of the standard AGP report

120 (<http://www.agpreport.org>), the aggregate daily overlay (ADO). This method uses Tukey
121 smoothing after rounding each timepoint to the nearest 10-minute mark, then plots the median,
122 inter-quartile range, and 5 and 95 percentiles at each time of day (with plans to add more options
123 in the future). The package also produces a similar aggregate plot with a Loess-smoothed
124 (locally estimated scatterplot smoothing) average overlaid on points representing every single
125 glucose value. For smaller data sets, this type of plot gives a meaningful overview of daily
126 glucose trends. Finally, the third type of plot uses a Loess-smoothed average for each patient
127 with glucose values color-coded by participant.

128 **Comparison of cgmanalysis package and proprietary software**


129 Our functions were compared to proprietary CGM software using clinically collected
130 data from iPro 2, Carelink 670G, Dexcom Clarity, and Diasend. The data were exported from
131 each platform, formatted using the `cleandata()` function, then summarized using the
132 `cgmvariables()` and `cgmreport()` functions. The data were not cleaned prior to plotting and
133 summary variable calculation, and summary variable parameters were altered from default (e.g.
134 defining an excursion as 15 minutes above or below threshold for iPro 2 data) in order to better
135 match the CGM results. Because each CGM device provides different and limited summary
136 variables, we were only able to compare a small subset of our package's output and were not
137 able to directly test more complex variables, such as MAGE or CONGA.

138

139 **Results**

140 **Fig 1** is an example of the ADO plot made using approximately 25,000 simulated CGM
141 values, and **Fig 2** is the version of the ADO with Loess smoothing, using the same data as in **Fig**
142 **1**. **Fig 3** is the patient-specific plot, made with a subset of the simulated data.

143 **Fig 1: Aggregate Daily Overlay (Tukey Smoothing)**




144

145 **Fig 2: Aggregate Daily Overlay (Loess Smoothing)**

146 **Fig 3: Daily Overlay per Subject (LOESS Smoothing)**

Subject ID



147

148 **Table 2** shows the results of summary variable comparisons between four different
149 proprietary CGM devices and our cgmanalysis package. Most of the differences in these
150 comparisons are small and the result of rounding. Overall the package appears to be capable of
151 reproducing proprietary calculations when run with non-default settings, although in the
152 comparison to the iPro 2, there was a difference of 1 high excursion.

153

154 **Table 2: Summary Variable Comparisons**

155 A. iPro 2 software (high excursion defined as > 140 mg/dL for 15 minutes, low defined as <
156 60 mg/dL for 15 minutes)

	cgmanalysis	iPro
# Sensor Values	2000	2000
Highest	282	282
Lowest	70	70
Average	126.87	127
Standard Dev	30.79	31
# High Excursions	31	32
# Low Excursions	0	0
% Time Above 140	24.85	24
% Time Below 60	0	0

157
158 B. Carelink 670G

	cgmanalysis	Carelink 670G
Average	123.65	124
Standard Dev	37.53	38

159
160 C. Dexcom Clarity

	cgmanalysis	Dexcom Clarity
Average	175.68	176
Standard Dev	67.10	68
Time in Range	55.66	56

161
162 D. Diasend

	cgmanalysis	Diasend
# Sensor Values	184	184
Highest	411	411
Lowest	54	54
Average	193.23	193
Standard Dev	89.67	89
Values above 200	44.57%	44.57%

163

164 **Figs 4a-d** show the comparisons of the graphical outputs produced by the proprietary
165 software and the cgmanalysis package. In the graphs produced by the cgmanalysis package,
166 glycemic patterns at each hour of the day are clearly visible and match the CGM device outputs
167 well. However, some of the proprietary software appear to apply different smoothing
168 algorithms, resulting in slightly different patterns across time.

169 **Fig 4a: “cgmanalysis” Package Plots Compared to iPro 2 Daily Overlay**

170 Clockwise from top left: Aggregate Daily Overlay (Tukey Smoothing), Aggregate Daily Overlay
171 (Loess Smoothing), iPro 2 Daily Overlay

172
173 **Fig 4a Tukey AGP (Top Left) Legend**

-- 5th & 95th Percentile

Interquartile Range

Median

174
175

176 **Fig 4b: “cgmanalysis” Package Plots Compared to Carelink 670G Daily Overlay**

177
178 Clockwise from top left: Aggregate Daily Overlay (Tukey Smoothing), Aggregate Daily Overlay
179 (Loess Smoothing), Carelink 670G Daily Overlay

180
181 **Fig 4b Tukey AGP (Top Left) Legend**

-- 5th & 95th Percentile

Interquartile Range

Median


182

183

184 **Fig 4c: “cgmanalysis” Package Plots Compared to Dexcom Clarity Daily Overlay**


185
186 Clockwise from top left: Aggregate Daily Overlay (Tukey Smoothing), Aggregate Daily Overlay
187 (Loess Smoothing), Dexcom Daily Overlay
188

189 **Fig 4c Tukey AGP (Top Left) Legend**




190

191 **Fig 4c Dexcom Clarity (Bottom) Legend**




192

193 **Fig 4d Tukey AGP (Top Left) Legend**



194

195 **Fig 4d Tukey AGP (Bottom) Legend**



196

197

198 **Fig 4d: “cgmanalysis” Package Plots Compared to Diasend Daily Overlay**

199

200 Clockwise from top left: Aggregate Daily Overlay (Tukey Smoothing), Aggregate Daily Overlay
201 (Loess Smoothing), Diasend Daily Overlay

202

203 **Discussion**

204 The summary variables produced by the cgmanalysis package match those from the
205 proprietary software for all platforms assessed, and differences are mainly due to rounding
206 discrepancies. Compared to the iPro 2, the number of high excursions differed by 1. Without
207 access to the iPro algorithms we are unable to determine why these counts disagree, but the
208 difference is not likely of clinical significance. The graphical outputs from the cgmanalysis
209 package are similar to the CGM device output in terms of the glycemic patterns by hour of day,
210 although there are small differences, likely due different smoothing algorithms.

211 There are several limitations to our comparison of the cgmanalysis package to the
212 proprietary software output. CGM devices only calculate a few summary variables, and
213 accordingly it is difficult to test this package cohesively. Also, gold standard calculations do not
214 exist for many of these variables, which makes verifying our results difficult. We hope that by
215 making this package freely available and open source, these limitations will be minimized
216 through widespread testing. Perhaps the greatest limitation to the software itself is the lack of an
217 easy to use graphical user interface (GUI), which may prevent its use by clinicians with limited
218 programming experience. We have included detailed documentation in the CRAN package, as
219 well as a new-user guide on GitHub, but using the package still requires enough technical
220 knowledge that it may be inaccessible to some users. None of the authors are software engineers,
221 and the package is undoubtedly less efficient than it could be. Again, we hope that the free and
222 open source nature will contribute significantly to improving the code over time, both as a result
223 of outside contributions and our own planned updates.

224 In conclusion, our software provides a standardized, free, open-source approach to
225 manage and analyze CGM data, enabling sharing of data across technology platforms,
226 collaboration between research groups, and more effective use of the growing pool of CGM data.
227 The advantage of using R functions rather than licensed statistical software, or a web-based or
228 desktop application, is that R is freely available and open source. Clinicians or investigators can
229 alter the code according to their needs and anyone can contribute to the development of the
230 program, as CGM research and technology advance.

231

232

233 **References**

234

- 235 1. DeSalvo DJ, Miller KM, Hermann JM, Maahs DM, Hofer SE, Clements, MA, et al.
236 Continuous glucose monitoring and glycemic control among youth with type 1 diabetes:
237 International comparison from the T1D Exchange and DPV Initiative. *Pediatr Diabetes*.
238 2018;19(7):1271-1275.
 - 239 2. Beck RW, Bergenstal RM, Riddlesworth TD, Kollman C, Li Z, Brown AS, et al.
240 Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials.
241 *Diabetes Care*. 2018.
 - 242 3. Bergenstal RM, Beck RW, Close KL, Grunberger G, Sacks DB, Kowalski A, et al.
243 Glucose Management Indicator (GMI): A New Term for Estimating A1C From
244 Continuous Glucose Monitoring. *Diabetes Care*. 2018;41(11):2275-2280.
 - 245 4. Hernandez TL, Barbour LA. A Standard Approach to Continuous Glucose Monitor Data
246 in Pregnancy for the Study of Fetal Growth and Infant Outcomes. *Diabetes Technology
247 & Therapeutics*. 2013;15(2):172-179.
 - 248 5. Hill NR, Oliver NS, Choudhary P, Levy JC, Hindmarsh P, Matthews DR. Normal
249 reference range for mean tissue glucose and glycemic variability derived from continuous
250 glucose monitoring for subjects without diabetes in different ethnic groups. *Diabetes
251 Technol Ther*. 2011;13(9):921-928.
 - 252 6. Sechterberger MK, Luijck YM, DeVries JH. Poor agreement of computerized calculators
253 for mean amplitude of glycemic excursions. *Diabetes Technol Ther*. 2014;16(2):72-75.
 - 254 7. Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH, et al.
255 International Consensus on Use of Continuous Glucose Monitoring. *Diabetes Care*.
256 2017;40(12):1631-1640.
 - 257 8. Hernandez TL, Barbour LA. A standard approach to continuous glucose monitor data in
258 pregnancy for the study of fetal growth and infant outcomes. *Diabetes Technol Ther*.
259 2013;15(2):172-179.
 - 260 9. Baghurst PA. Calculating the mean amplitude of glycemic excursion from continuous
261 glucose monitoring data: an automated algorithm. *Diabetes Technol Ther*.
262 2011;13(3):296-302.
 - 263 10. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic
264 data capture (REDCap)--a metadata-driven methodology and workflow process for
265 providing translational research informatics support. *J Biomed Inform*. 2009;42(2):377-
266 381.
- 267




Figure 1






Figure 4b






Figure 4c






Figure 4e




Figure 2




Figure 3






Figure 4a